Sandhoff disease is an autosomal recessive lysosomal storage disease included in the group of GM2 gangliosidoses. It is caused by biallelic variants in the HEXB gene, which lead to a combined deficiency of beta-hexosaminidase A and B. As a consequence, GM2 gangliosides and other glycolipids accumulate, mainly in the nervous system, causing progressive neurodegeneration.
Sandhoff disease
The HEXB gene provides instructions for making the beta subunit of the beta-hexosaminidase A and beta-hexosaminidase B enzymes. Hexosaminidase A is composed of an alpha and a beta subunit, whereas hexosaminidase B contains two beta subunits. Both are involved in the lysosomal degradation of GM2 gangliosides and other glycoconjugates, molecules particularly abundant in nerve cells.
Pathogenic variants in HEXB reduce or eliminate the function of the beta subunit, markedly decreasing the activity of both hexosaminidases. This blockade prevents the normal degradation of GM2 gangliosides and leads to their progressive accumulation within lysosomes, especially in neurons. The disease forms a clinical spectrum including acute infantile, juvenile, and late-onset forms; severity typically correlates with residual enzyme activity. It is inherited in an autosomal recessive pattern: an affected individual must inherit two pathogenic variants, one from each parent. The overall prevalence is very low, although higher frequencies have been described in some populations with founder variants, such as Creole communities in northern Argentina, Métis groups in Saskatchewan, or the Maronite community in Cyprus.
Symptoms
The classic infantile form typically begins before 6 months of age. Following apparently normal initial development, progressive weakness, delay or loss of motor milestones, hypotonia, exaggerated startle reflex, seizures, and neurological deterioration appear. A cherry-red spot on the macula, progressive macrocephaly, and frequently hepatosplenomegaly may also be observed. Juvenile forms begin later, with developmental regression, gait disturbance, dysarthria, dysphagia, and seizures. Late-onset forms can present in adolescence or adulthood with weakness, ataxia, dysarthria, neuropathy, movement disorders, and in some cases, cognitive or psychiatric disturbances.
Disease management
Currently, there is no approved curative treatment to halt neurodegeneration in Sandhoff disease. Management is symptomatic and supportive, aimed at maintaining nutrition and hydration, reducing the risk of aspiration, controlling seizures, and treating respiratory, motor, and feeding complications. In juvenile and late-onset forms, physical therapy, occupational therapy, speech therapy, and mobility or communication aids are important. Follow-up should be multidisciplinary and periodic. Once familial variants are identified, genetic counseling, carrier screening, and reproductive options such as prenatal or preimplantation diagnosis can be offered.
Genes analyzed
Bibliography
Grunseich C, Schindler AB, Chen KL, et al. Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency. J Neurol. 2015;262(4):1066-8.
Kleiman FE, de Kremer RD, de Ramirez AO, et al. Sandhoff disease in Argentina: high frequency of a splice site mutation in the HEXB gene and correlation between enzyme and DNA-based tests for heterozygote detection. Hum Genet. 1994 Sep;94(3):279-82.
Tim-Aroon T, Wichajarn K, Katanyuwong K, et al. Infantile onset Sandhoff disease: clinical manifestation and a novel common mutation in Thai patients. BMC Pediatr. 2021 Jan 7;21(1):22.
Delnooz CC, Lefeber DJ, Langemeijer SM, et al. New cases of adult-onset Sandhoff disease with a cerebellar or lower motor neuron phenotype. J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):968-72.
